Harnessing the cytotoxic granule exocytosis to augment the efficacy of T-cell-engaging bispecific antibody therapy.

Mika Casey(QIMR Berghofer Medical Research Institute), Kyohei Nakamura(QIMR Berghofer Medical Research Institute), Carol Lee(QIMR Berghofer Medical Research Institute), Rebecca L. Johnston(QIMR Berghofer Medical Research Institute), Sharon M. Hoyte(QIMR Berghofer Medical Research Institute), Simon J. Harrison(Peter MacCallum Cancer Centre), Maher K. Gandhi(Translational Research Institute), Wing Yu Kwok(QIMR Berghofer Medical Research Institute), Soi Cheng Law(Translational Research Institute)
Haematologica
January 25, 2024
10.3324/haematol.2023.284435
Cited by 2

Related Papers

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
|Nature Immunology|2017|639
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
|The Lancet|2019|636
Genome-wide analysis of long noncoding RNA stability
|Genome Research|2012|592
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
|Leukemia|2009|586